{"created":"2023-06-19T09:40:18.772883+00:00","id":463,"links":{},"metadata":{"_buckets":{"deposit":"5cf1b312-33a4-4ca2-8c6d-e7af1d554570"},"_deposit":{"created_by":18,"id":"463","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"463"},"status":"published"},"_oai":{"id":"oai:yasuda-u.repo.nii.ac.jp:00000463","sets":["7:48"]},"author_link":["945","946"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-02-28","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"47","bibliographicPageEnd":"300","bibliographicPageStart":"289","bibliographic_titles":[{"bibliographic_title":"安田女子大学紀要","bibliographic_titleLang":"ja"},{"bibliographic_title":"Journal of Yasuda Women's University","bibliographic_titleLang":"en"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"がん治療における薬物療法では従来の殺細胞性の抗がん剤には限界があり、分子標的治療薬が登場した。近年、免疫チェックポイント阻害薬が悪性黒色腫をはじめとして多くのがん腫で再発、進行がんを対象に第Ⅲ相試験が行われ一定の効果が得られることから免疫療法として使用されるようになった。しかし、従来の抗がん剤ではみられなかった内分泌障害や消化管障害などの免疫関連有害事象が起こることが明らかとなった。それらに対しては、発症に早期に気づき対処することが求められる。悪性黒色腫に対しニボルマブやイピリムマブを投与し有害事象を来した自験例を示し考察を加えた。起こりうる免疫関連有害事象は多くの臓器に多岐にわたるので、治療科の医師のみでなく、腫瘍内科医、内分泌・代謝内科、消化器内科等の医師および、施設内の看護師、薬剤師を含めた診療連携体制が極めて重要であることを強調した。","subitem_description_type":"Abstract"}]},"item_10002_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24613/00000444","subitem_identifier_reg_type":"JaLC"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"安田女子大学"}]},"item_10002_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00242368","subitem_source_identifier_type":"NCID"}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0289-6494","subitem_source_identifier_type":"PISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"宮原, 裕","creatorNameLang":"ja"},{"creatorName":"ミヤハラ, ヒロシ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Miyahara, Hiroshi","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-03-20"}],"displaytype":"detail","filename":"02896494047029.pdf","filesize":[{"value":"1.4 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"02896494047029.pdf","url":"https://yasuda-u.repo.nii.ac.jp/record/463/files/02896494047029.pdf"},"version_id":"ab8580ee-251d-4a7a-8ffc-41f43093efc1"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"免疫療法","subitem_subject_scheme":"Other"},{"subitem_subject":"免疫チェックポイント阻害薬","subitem_subject_scheme":"Other"},{"subitem_subject":"免疫関連有害事象","subitem_subject_scheme":"Other"},{"subitem_subject":"副腎皮質機能障害","subitem_subject_scheme":"Other"},{"subitem_subject":"ステロイド","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"免疫チェックポイント阻害薬の副作用と対策","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"免疫チェックポイント阻害薬の副作用と対策","subitem_title_language":"ja"},{"subitem_title":"Dysimmune toxicities and management of immune checkpoint blockade","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"18","path":["48"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2019-03-20"},"publish_date":"2019-03-20","publish_status":"0","recid":"463","relation_version_is_last":true,"title":["免疫チェックポイント阻害薬の副作用と対策"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2024-01-26T05:54:44.299970+00:00"}